

Contact: Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732

Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144

Angels Initiative, initiated by Boehringer Ingelheim and in Collaboration with IQVIA, Named Best Service Delivery in 2018 Health Collaboration Awards

Delivering transformational change in how stroke patients receive care across multiple countries

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C. – January 10, 2019 – **IQVIA™** (NYSE:IQV) today announced that the Angels Initiative for improving care for stroke patients has been awarded the 2018 Health Collaboration Award for Best Service Delivery by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The Angels Initiative is a non-commercial healthcare program by [Boehringer Ingelheim](#), in Europe in close collaboration with IQVIA focused on improving stroke care. The project is endorsed by the European Stroke Organisation and World Stroke Organisation as well as the Stroke Alliance for Europe (SAFE), RESQ, SITS, QASC Europe, Medtronic, Brainomix and many other institutions and communities dedicated to improving stroke care globally. IQVIA's management and administration of the initiative includes: hospital enrollment, on-site consultancy, as well as training and education of healthcare professionals regarding stroke-patient care.

"We are very pleased with the quality of the work and the motivation of the IQVIA Angels consultants. The collaboration with IQVIA contributes significantly to the success of Angels," commented Thomas Fischer, Head of the Global Angels Initiative.

Reviewing more than 80 applications, an esteemed jury appointed by EFPIA selected the Angels Initiative as a program of distinction, describing it as, "a very impressive strategic project with clear objectives and excellent collaboration across a wide range of countries and stakeholders."

The overall strategy of the Angels Initiative is to increase the number of "stroke-ready" hospitals and to optimize the quality of treatment in existing stroke centers. A crucial element of the implementation of the initiative are the Angels Consultants spending time with doctors, nurses and ambulance crews to create and improve the treatment pathways and processes around stroke care.

"Only in Europe every 30 minutes, a stroke patient dies or is permanently disabled — not only due to the stroke itself, but because they were treated in the wrong hospital. This initiative seeks to change that," said Chris Pepler, senior vice president, Contract Sales and Medical Solutions at IQVIA. "As part of this initiative, IQVIA is delighted to see our efforts recognized by the EFPIA and, together with collaborating organizations, we will continue to strive to improve stroke care worldwide."

Since its launch in 2017, the Angels Initiative has enrolled nearly 2500 hospitals from more than 60

countries, positively affecting the treatment of 1.3 million stroke patients.

Additional information about the Angels Initiative is available at <https://www.angels-initiative.com/>.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

#